CC BY-NC-ND 4.0 · Rev Bras Ortop (Sao Paulo) 2019; 54(02): 219-222
DOI: 10.1016/j.rboe.2017.11.017
Case Report | Relato de Caso
Sociedade Brasileira de Ortopedia e Traumatologia. Published by Thieme Revnter Publicações Ltda Rio de Janeiro, Brazil

Cervical Osteoblastoma: A Case Report[*]

Article in several languages: português | English
Carolina Oliveira
1  Departamento de Cirurgia Ortopédica, Unidade Local de Saúde do Alto Minho, Viana do Castelo, Portugal
,
Luísa Vital
2  Departamento de Cirurgia Ortopédica, Hospital de São João, Faculdade de Medicina, Universidade do Porto, Porto, Portugal
,
Francisco Serdoura
2  Departamento de Cirurgia Ortopédica, Hospital de São João, Faculdade de Medicina, Universidade do Porto, Porto, Portugal
,
André Rodrigues Pinho
2  Departamento de Cirurgia Ortopédica, Hospital de São João, Faculdade de Medicina, Universidade do Porto, Porto, Portugal
,
Vitorino Veludo
2  Departamento de Cirurgia Ortopédica, Hospital de São João, Faculdade de Medicina, Universidade do Porto, Porto, Portugal
› Author Affiliations
Further Information

Publication History

16 September 2017

21 November 2017

Publication Date:
10 May 2019 (online)

Abstract

Osteoblastoma is a rare benign primary bone tumor. It accounts for 3% of benign and 1% of all primary bone tumors. The treatment goal is complete surgical resection. This treatment limits the risk of recurrence. As osteoblastoma is a highly vascular tumor, complete resection is often difficult. This report describes the case of a 19-year-old male patient who presented severe right-sided neck and shoulder pain. The computed tomography scan revealed a mass lesion on C7 compatible with osteoblastoma. Preoperative embolization and tumor resection were performed. At the 3-year follow-up, the patient had no restrictions on daily activities, and, to date, there has been no evidence of recurrence.

* Study conducted at Departamento de Cirurgia Ortopédica, Hospital de São João, Faculdade de Medicina, Universidade do Porto, Porto, Portugal. Published originally by Elsevier Ltda.